Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients with Relapsed or Refractory B-cell NHL

Clinical trial NCT05233033 · COMPLETED

Trial details

NCT number: NCT05233033
Sponsor: Kymera Therapeutics, Inc.
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Non Hodgkin Lymphoma Diffuse Large B Cell Lymphoma DLBCL MYD88 Gene Mutation

Start date: 2022-06-13
Primary completion: 2023-07-28
Enrollment: 7

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.